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Abstract
Background: Doping with anabolic androgenic steroids in sports has now developed to a widespread use of
these agents among young people outside the sport. This is of major concern to the society. The purpose of the
use is mainly for aesthetic reasons and is seen as a male phenomenon. But use also occurs in women where the
knowledge is scarce. Our aim was to identify the pattern of doping agents in eight female cases and compare
them with similar data from men.
Methods: Eight female users were recruited through Anti-Doping Hot-Line, a national telephone counseling service
on doping issues during the years 1998–2004. The use was confirmed with urine doping analysis at the Doping
Laboratory. The characteristic of use, co-use of narcotics/other doping agents, exercise pattern, adverse-side effects,
family history and reason to begin was evaluated.
Results: The women used on average 1.9 different anabolic androgenic steroids and clenbuterol preparations.
Ephedrine and growth hormone were co-used in five and one of the women, respectively. Three women reported
co-use of narcotics (cannabis and cocaine).
The average duration of anabolic agent use before contacting health care was 58 weeks (range 7–104). Side effects
for anabolic androgenic steroids (n = 5) included voice changes, clitoral enlargement, body hair growth, whereas
women using clenbuterol (n = 2) reported tachycardia and depression. All women except one had a man in close
relationship encouraging them to begin with the doping agents.
Conclusions: The use of doping agents in our eight women was different from that in male users. The women
used less doping agents and were more prone to contact the health care, at an earlier stage, probably due to the
adverse effects. The co-use with ephedrine, growth hormone and cannabis appeared to be in the same range as in
men. This is the first study showing that a man in close relationship may motivate a woman to use anabolic agents.
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Background
Anabolic androgenic steroids (AAS) including testosterone,
other endogenous androgenic hormones and synthetic
compounds structurally related to these compounds, are
commonly used by athletes to improve muscle mass and
enhance exercise performance. AAS are the most
frequently detected doping agents, testosterone being the
predominant steroid (http://www.wada-ama.org). Notably,
the use of these agents among nonprofessional athletes, as
well as among individuals who want to enhance their
physical appearance, is a growing public health problem
and has become a major concern to the society [1–3].
Even though AAS use is mainly considered a male
phenomenon, it is not limited to men. It has been esti-
mated that the lifetime prevalence of AAS use is around
0.1 % in women [4]. Questionnaire surveys indicate that
the numbers may be even higher among adolescent girls
where lifetime prevalence values of 0.1–7.3 % have been
reported [4–8]. However, some of these studies have prob-
ably over-estimated the prevalence since the questions
used sometimes failed to distinguish between anabolic ste-
roids, corticosteroids, and over-the-counter supplements
that the respondents might have confused with steroids
[4]. Nevertheless, AAS may develop to a health problem
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also in women [7] and preventive measures in the society
are warranted [9].
Even though the illicit use of AAS may be considered a
health problem in women, little is known about this group
of users. The use of AAS in women and adolescent girls is
highly associated with sport activity, body-building and
weightlifting [7, 10], but the motives for starting the use of
AAS have not been investigated in women.
In general, women appear to prefer doping class agents
other than AAS, particularly those associated with weight
loss, such as ephedrine and clenbuterol [7]. Clenbuterol
which is a long-acting beta-2-agonist used in veterinary
medicine [11] is classified as an anabolic agent according
to WADA (www.wada-ama.org), since it exerts anabolic
effects [12].
The negative side effects of AAS use in women include
enlargement of the clitoris, deepening of the voice, in-
creased facial hair, menstrual disorders, and acne. Changes
in mood such as depression, irritation and aggression have
also been reported [5, 7, 13, 14]. To our knowledge, the
negative effects of clenbuterol abuse in women have not
been described in literature.
Our aim was to identify the pattern of AAS and clenbu-
terol use in women and compare with similar data reported
in men. The causes for initiating an illicit use, co-use of
other doping agents and narcotics, as well as any side
effects, reported or observed, were also assessed.
Methods
Eight women were recruited to the study between 1998
and 2004 via the Anti-Doping Hot-Line at the Dept of
Clinical Pharmacology, Karolinska University Hospital, a
free telephone counseling service for individuals affected
by, or concerned with use of doping agents [2]. During
the study period the Anti-Doping Hot-Line received
4339 phone calls and of these, 216 phone calls were
from women with own doping experience [2]. Some of the
women were calling several times and therefore the exact
numbers of women calling during this period was not
documented. Approximately 50 women were concerned
about their side-effects of AAS and/or clenbuterol and
were asked to participate in this study. A genuine desire
to give up using anabolic agents (AAS or clenbuterol) was
a prerequisite to be included. A flow chart describing the
collection procedure is presented in Fig. 1.
Participation was commenced after informed consent,
and no economical remuneration was given. Male users
were also recruited (n = 56) and the results regarding their
demographics, side effects and co-abuse have already been
published [15, 16]. The project was approved by the Ethics
Committee of the Karolinska Institutet, Stockholm,
Sweden. Blood and urine samples were collected at the
visit. The urine samples were analyzed for AAS and other
doping agents using the methods employed at that time in
the WADA accredited Doping Laboratory, and for nar-
cotic substances by routine screening methods at the
Drugs of Abuse Laboratory, both at the Department of
Clinical Pharmacology, Karolinska University Hospital.
The cholesterol profile (HDL, LDL) and hemoglobin (Hb)
were analyzed by routine methods at the Department of
clinical chemistry (Karolinska University Hospital). All
participants were personally interviewed by a study nurse
including questions about 1) demographics 2) details
about AAS use history and pattern 3) motives for starting
AAS 4) co-use of other doping agents and narcotic
substances 5) exercise pattern 6) family background and
7) any experienced side effects. If necessary, individuals
were referred to qualified medical specialist at the hos-
pital clinics of psychiatry or endocrinology and/or to a
gynecologist.
Fig. 1 Flow chart of the participant recruitment through the study
period 1998–2004
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Results and discussion
Background information and motives for starting AAS use
Most of the women reported a troublesome family
history such as growing up without parents (n = 2), split
families (n = 5), parents that were violent (n = 1), men-
tally ill (n = 1) or alcoholics (n = 1). One woman reported
a suicide attempt and eating disorder (anorexia and bu-
limia) during her youth. In a previous study, Ip et al.
noted that 25 % of female AAS users display bulimia,
whereas eating disorders in male AAS users are very rare
[5]. No one reported any sexual abuse or harassments
which have been reported in other studies of female
AAS users [5, 17, 18].
In agreement with previous studies most of the females
herein (n = 7) were involved in bodybuilding and/or
strength training [5, 7, 10] and four of them were compet-
ing in body-building (Table 1). K7 was the only woman
that did not report any involvement in strength training,
but had interest and participated in sport activities includ-
ing handball.
Of the eight women included in the study, six reported
that their boyfriend was using AAS, and that the boy-
friend impact on the decision to start had been crucial.
One woman (K6) was deceived by her father to take
clenbuterol for losing weight, and she believed that,
based on her observed effects that her father also gave
her AAS. Another woman (K3) was the only participant
that took the decision on her own to start the use of an
anabolic agent without being deceived or influenced by a
man, (Table 1).
Our findings are interesting as, to our knowledge, there
is only one previous case report of a woman who was
introduced to use AAS by her boyfriend [17]. This novel
finding that AAS/clenbuterol use in women is initiated by
a man in a close relationship, would be interesting to in-
vestigate further in other AAS using female populations.
AAS use in men is predominantly motivated by a desire
for their anabolic effect, i.e., to attain a nice and strong
body [19–22]. The influence of a peer seems to be rare
among male AAS users although such cases have been
reported [20, 23].
Characteristics of the female AAS-users
The mean age was 23.0 years (SD 5.7, range 16–31) and
the participants reported to have started their AAS and/
or clenbuterol use at the mean age of 21.7 years (SD 5.9,
range 15–29). The latter is similar to that reported in
men included in the same study population [15], as well
as among AAS using men seeking help at a substance
abuse center [19].
The duration of AAS/clenbuterol use when contacting
the Anti-Doping Hot-Line varied between 7 weeks and
2 years (mean 58 weeks). At the visit the subjects reported
that their latest intake was between 0 and 25 weeks earlier
(Table 2). In men the reported mean duration of AAS when
contacting the Anti-Doping Hot-Line was 5.2 (0.5–17)
years. [15] Similar figures (0.5–17 years) have also been
reported elsewhere [19]. Thus, females reported markedly
shorter duration of anabolic agents use than men, which
could be explained by negative side effects being more
bothering or apparent, and causing more concerns in
women, resulting in women to be more prone to contact
health–care givers. In general unwanted AAS related side
effects are more often reported in women than in men [5],
probably since women have lower testosterone levels and
are more sensitive to exogenous administration of steroidal
agents [24].
AAS/clenbuterol use (self-reported and confirmed by
analysis)
Of the eight women included in the study, four
reported use of clenbuterol, four reported use of
Winstrol (stanozolol), two individuals use of Primobo-
lan (methenolone enanthate) and two Deca-Durabol
(nandrolone). One of the women claimed that she
had probably been using an unknown AAS previously.
Of the eight women, three were positive for all the
doping agents that they actually reported (Table 2).
The fact that the self-reported compounds did not
fully match the substances found in urine tests is
consistent with previous studies in women [7] and in
men. [25] One of the women tested positive for nan-
drolone, a substance she did not report. This could
be due to nandrolone contamination of any other
Table 1 Self-reported motives for using AAS/clenbuterol in
eight female users of AAS
Subject Athletics Motives for starting AAS
K1 Strength training/competition
in bodybuilding
Wants to increase performance.
Lives with AAS using boyfriend
K2 Strength training/competition
in bodybuilding
Her boyfriend uses AAS and
insisted her to take clenbuterol
even though she did not want
to. Planning to use AAS
K3 Strength training To increase muscle size and
decrease fat
K4 Strength training To increase performance,
Convinced by AAS using
boyfriend
K5 Strength training, Group
training, Works in a gym
Recommendation from her
ex-partner which was a AAS user
K6 Playing handboll and
other sports
Have been tricked by her father








Convinced by AAS using
boyfriend
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agents she used, including nutritional supplements, as it
has been reported that nandrolone has been found in sup-
plements [26, 27]. It could also be due to memory default,
in particular since nandrolone can be detected for several
months after the last intake [15, 28].
The females used on average 1.9 (range 1–3) different
AAS/clenbuterol preparations. The women that were only
using AAS, reported on average 1.6 (range 1–2) different
AAS compounds. This is similar to the results of an inter-
net based survey showing that female AAS users used on
average 1.2 (range 1–2) AAS per cycle, with the corre-
sponding number in men being higher 2.3 (range 1–7) [5].
The supposed basis for using several types of AAS is to
maximize androgen receptor binding and to activate
multiple steroid receptor sites. Only two of the women re-
ported use of an injectable steroid. In contrast, the majority
of males use injectable AAS formulations [29, 30]. This
gender difference with females preferring lower doses and
oral administration has also been acknowledged by Ip et al.
[5] Women are probably using lower doses and fewer AAS
agents to minimize the negative side effects of AAS.
Co-use of other substances
In addition to AAS/clenbuterol, ephedrine and growth
hormone were co-used in five and one of the women, re-
spectively. These doping agents are known to be more
common among AAS users as compared to women not
using AAS [7, 31]. According to a metaanalysis conducted
by Sagoe et al. [32] both ephedrine and growth hormone
are on the 10-top list as the most popular substances to
co-use in males using AAS. Three women reported co-use
of narcotics (cocaine and cannabis), and two of them
tested positive for cannabis. This is a somewhat higher
proportion than observed in a previous study where 24 %
of female AAS users were reported to use narcotics [18].
The corresponding number in men included in the male
population collected at the same time period, was only
5 % tested positive on narcotics whereas about 40 %
reported a co-use [15]. Similar frequencies were also
reported in more recent studies where 30–50 % of AAS
using males were also using cannabis [20, 22, 33, 34].
These results indicate that the prevalence of narcotic use,
at least of cannabis, may be similar in AAS using women
and men.
Reported side effects
All AAS using women reported the classical side effects
associated with AAS in women such as clitoral enlarge-
ment and voice changes. Other side effects were acne,
body hair growth, menstrual disturbance and mood
changes i.e., irritation, aggression and depression (Table 3).
There are indications that women have a tendency to
underestimate their side effects. It has been noticed that
even though female AAS users exhibit apparent deep
voice, many do not report that as a side effect [7]. It is
possible that since the women included in our study had
spontaneously contacted the anti-doping hotline, they
were more alerted and concerned about their side effects
than of female AAS users in general.
The two women on clenbuterol reported only depres-
sion and tachycardia (Table 3). Case studies indicate that
clenbuterol may cause cardiac ischemia and rhythm
disturbances [35] and myocardial infarction [36] in body-
building men. However, data on illicit use of clenbuterol
in women are scarce. Patients reporting clenbuterol over-
dose also present with tachycardia as well as tremor, chest
pain, headache, nausea etc. [11]. One of the women using
only clenbuterol also reported tremor as a side effect,
which is a common side effect of all beta-adrenoceptor
agonists. In fact, some athletes discontinue the admin-
istration of clenbuterol due to disturbing tremor [37].
Clenbuterol is promoted as an anabolic agent with fat
burning, weight loosing and performance enhancing prop-
erties [35, 38]. Since it is a popular doping substance
Table 2 Characteristics of AAS use in the study group at the time of inclusion
Subject Age Self- Reported,
AAS/clenbuterol










K1 24 Primobolan, Winstrol methenolone (1621 ng/mL)
stanozolol (116 ng/mL)
3 2 years Cannabis Cannabis
K2 27 Clenbuterol clenbuterol (42 ng/mL) 0a 8 months None Negative
K3 29 Clenbuterol Negative 1 3.5 months ephedrine None Negative
K4 31 Winstrol, Primobolan stanozolol (56.8 ng/mL)
nandrolone (17.4 ng/mL)
14 2 years Growth hormone,
ephedrine
None Negative
K5 20 Winstrol Negative 25 7 weeks Cocaine Negative
K6 16 Clenbuterol Negative 12 3 years ephedrine None Negative
K7 21 Metandrostenolone,
Deca-Durabol, Clenbuterol
Negative 1 2 years ephedrine None Negative




5 1 year ephedrine Cannabis Cannabis
ashe used the day before visit
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among AAS using women [18] and men [39] as well
among elite athletes (https://www.wada-ama.org) it is
important to understand the medical consequences of
using this drug.
Cardiovascular biomarkers
It is well known that supra-physiological doses of AAS
have detrimental effects on the lipid profile and Hb
levels in men as reviewed in [40], whereas studies in
women are scarce. The mean (±SD) concentrations of
total cholesterol, HDL, LDL and Hb were 4.0 ± 0.9
mmol/L, 1.2 ± 0.5mmol/L, 2.6 ± 0.9 mmol/L and 135 ±
10 g/L, respectively (individual data given in Table 3).
These values are in the normal range for women and
were not as high as in male AAS users where mean LDL
and Hb values of 3.2 mmol/L and 162 g/L, respectively,
were observed [15, 16]. However, it is not possible to
draw any conclusions based on this low number of indi-
viduals since the lipid and Hb profile is highly dependent
not only on dose and type of AAS but also on age, diet,
exercise, genetics etc. [41–46].
Our report has some limitations that need to be ad-
dressed. First, the study is only based on 8 cases, a much
smaller number than many studies in men. However,
studies in women are more difficult since AAS use is
much rarer. Second, the way of recruitment implicates a
selection bias since the women contacted the health care
on own initiative. Moreover, our selection criteria did not
allow us to conduct studies in women that did not want
to quit their AAS/clenbuterol use. It is possible that these
women did not experience side effects (at least not yet)
and that the utilization profile was different. For these
reasons our results may not be representative for other
groups of AAS and/or clenbuterol using women. How-
ever, because of the scarcity of knowledge on doping in
women we believe the results presented here are of inter-
est. One advantage of this study is that it was not based
solely on self-reported data, since AAS intake was
confirmed by urine analyses and the nurse’s assessment of
the health status.
Conclusion
This is the first study showing that a male partner or
another man in close relationship may trigger use of AAS/
clenbuterol in women. The women used fewer AAS sub-
stances and they were more prone to contact the health
care at an earlier stage than men. This may be explained
by a higher female inclination to experience many of the
side effects. In accordance with earlier studies, several
adverse effects were noted including clitoral enlargement,
voice changes, menstrual disorders, acne, and mood
changes. Ephedrine, growth hormone and cannabis were
substances that were frequently co-used. These substances
are also popular among AAS using males. General
knowledge about AAS use in sports and in the society is
important for the medical community and other people
dealing with AAS users. This will improve our strategies
for prevention and treatment. Our results indicate that
not only treatment directions but also future preventing
programs may be different between men and women.
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Table 3 Adverse effects, reported and observed, in women
using AAS or clenbuterol






K1 Clitoral enlargement, voice
change, body hair growth,
menstrual disorders
4.2 0.7/3.3 135




K4 Clitoral enlargement, voice
change, menstrual disorders,
acne, body hair growth
3.8 0.6/3 154
K5 Enlarged clitoris, voice change,
body hair growth, acne,
menstrual disorder
3.6 1.5/1.9 134
K6 Clitoral enlargement, voice
change, menstrual disorders,





K7 Clitoral enlargement, voice
change, menstrual disorders,
acne, mood changes, depression,
lost hair head
4.3 1.9/2.0 134
K8 Clitoral enlargement, voice
change, mood swings,
stretch marks, reduced breast
3.2 0.7/2.2 128
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